HIVR4P Kicks off with Multiple Announcements of Progress in HIV Prevention
Advances in PrEP options and HIV vaccine research were unveiled at the 5th HIV Research for Prevention (HIVR4P) Conference in Lima, Peru.
The 5th HIV Research for Prevention (HIVR4P) conference, held in Lima, Peru, showcased groundbreaking advances in HIV prevention. Key findings included promising new data on long-acting HIV prevention methods, innovative technologies, and HIV vaccine research.
With nearly 1,500 participants attending both in person and virtually, the conference focuses on the potential for transforming HIV prevention globally, particularly in resource-limited areas.
Top 3 Takeaways:
Lenacapavir's Promise: New data from the PURPOSE 2 study show that twice-yearly lenacapavir injections for HIV prevention are highly effective, reducing HIV acquisition by 96%. This advancement could revolutionize HIV prevention for diverse populations.
Dapivirine Vaginal Ring Update: Research shows that the new three-month dapivirine vaginal ring is more effective than the current monthly version, offering women a more convenient and affordable HIV prevention option. Read more
Innovative Technologies: A refillable subdermal implant demonstrated the potential for ultra-long-acting HIV prevention, offering protection for over two years, which could significantly simplify prevention strategies.
These advancements bring hope for reducing HIV infections globally, with a focus on equitable access and human-centered approaches.